How To Deal With High Dose Opioids: Better Storage, Disposal And Advertising
Executive Summary
Beyond considering removal from the market, US FDA advisory panel suggests actions agency could take to improve the safety of higher dosage strength opioids.
You may also be interested in...
Will US FDA Remove Higher Strength Opioids From The Market?
Advisory committee members are divided on whether agency should restrict access to higher dose opioids, but most want option kept on the table.
Opioid Blister Pack Mandate Could Be Phased-In Based On Prescription Volume
US FDA seeks public input on potential advantages and challenges of requiring 5-, 10, and -15-count blister packs for certain opioids and the idea of staggering implementation.
RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.